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Abstract: Cardiovascular malformations are the most common type of birth defect and result in significant mortality 
worldwide. The etiology for the majority of these anomalies remains unknown but genetic factors are being recognized as 
playing an increasingly important role. Advances in our molecular understanding of normal heart development have led to 
the identification of numerous genes necessary for cardiac morphogenesis. This work has aided the discovery of an 
increasing number of monogenic causes of human cardiovascular malformations. More recently, studies have identified 
single nucleotide polymorphisms and submicroscopic copy number abnormalities as having a role in the pathogenesis of 
congenital heart disease. This review discusses these discoveries and summarizes our increasing understanding of the 
genetic basis of congenital heart disease. 
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INTRODUCTION 
  Congenital heart disease (CHD) is the leading cause of 
birth defects, and accounts for more deaths in the first year 
of life than any other condition when infectious etiologies 
are excluded [1]. With an incidence ranging from 19 to 75 
per one thousand live births and present in an even greater 
proportion of miscarriages, CHD is an important cause of 
childhood morbidity and mortality worldwide [2]. Despite 
advances in medical and surgical care, the etiology of CHD 
is still not completely understood; and with more children 
with CHD surviving to adulthood and starting families, it 
becomes even more critical to understand the origins of 
CHD. Classic studies including the Baltimore-Washington 
Infant Study have found that CHD is multifactorial, due to 
both genetic predisposition and environmental influences 
[3]. Sequencing of the human genome and advances in 
molecular techniques has led to increasing evidence impli-
cating a stronger role for genetic factors.  
  Over the past couple of decades, there has been a greater 
understanding of the molecular pathways regulating cardiac 
development. The development of gene targeting technology 
has led to the generation of a multitude of mouse models 
with cardiac developmental defects. These studies have led 
to the identification of numerous transcriptional regulators, 
signaling molecules and structural genes that are critical for 
normal cardiac morphogenesis. In addition, multiple genes 
have been identified that are controlled by these highly 
conserved molecular pathways. These investigations into the 
molecular mechanisms of cardiac development have assisted 
in the identification of genetic etiologies of CHD and pro-
vide evidence that many genes may have etiologic roles in 
human CHD. 
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  In this review, we will discuss the evolution of know-
ledge regarding genetic causes of CHD, from early evidence 
that aneuploidy was associated with CHD, to the later use of 
submicroscopic techniques such as fluorescence-in-situ 
hybridization, and more recently the identification of single 
gene mutations as a cause of CHD. We will focus on new 
developments in the field of cardiac genetics, specifically in 
relation to the importance of copy number variations and 
single nucleotide polymorphisms in the development of 
CHD.  
CARDIAC MALFORMATIONS ASSOCIATED WITH 
ANEUPLOIDY AND MICRODELETIONS 
  While most children born with CHD do not have other 
birth defects, CHD occurs in association with other 
anomalies or as part of an identified syndrome in 25 to 40% 
cases [4]. In addition, approximately 30% of children with a 
chromosomal abnormality will have CHD [5]. Aneuploidy, 
or abnormal chromosomal number, accounts for a significant 
proportion of CHD (Table 1). Fifty percent of individuals 
born with Trisomy 21 have CHD, ranging from atrial and 
ventricular septal defects to atrioventricular canal lesions. In 
Trisomy 13, the incidence increases to 80%, with heterotaxy 
and laterality defects becoming more common, and among 
individuals with Trisomy 18, nearly all will have CHD, 
usually in the form of septal defects. Approximately one-
third of females with Turner syndrome, or monosomy X, 
have CHD. The malformations are usually of the left-sided 
cardiac structures, and the most common diagnoses include 
bicuspid aortic valve, aortic stenosis, hypoplastic left heart 
syndrome, and coarctation of the aorta. In males with 
Klinefelter syndrome, or 47, XXY, there is a fifty percent 
incidence of CHD, with patent ductus arteriosus and atrial 
septal defects prevailing [5]. These and other less common 
chromosomal defects are detected in patients with CHD 
since the advent of the chromosomal G-banded karyotype. 
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of only five to ten megabases, limiting this technique in its 
ability to detect smaller chromosomal anomalies.  
  With the development of fluorescence in situ hybridi-
zation (FISH), a technique in which fluorescent labeled 
probes are hybridized to metaphase chromosomes to detect 
small submicroscopic chromosomal deletions and dupli-
cations, several syndromes caused by chromosomal abnor-
malities have been elucidated (Table 1). Two classic exam-
ples include the 22q11 deletion syndrome and Williams-
Beuren syndrome. The 22q11 deletion syndrome (also 
known as DiGeorge, velo-cardio-facial and conotruncal ano-
maly face syndromes) is caused by a microscopic deletion on 
chromosome 22q11.2, and leads to cardiac malformations 
along with thymic and parathyroid hypoplasia and charac-
teristic dysmorphic facies, due to abnormal pharyngeal arch 
development [6]. The most common cardiac malformations 
are interrupted aortic arch, truncus arteriosus, and tetralogy 
of Fallot, and routine genetic testing is now performed in 
patients with these heart lesions [7]. Williams-Beuren 
syndrome, characterized by cardiac defects, most commonly 
supravalvar aortic and pulmonary stenosis as well as peri-
pheral pulmonary stenosis, in addition to typical elfin facies, 
infantile hypercalcemia, renal involvement, and cognitive 
disability, is due to microdeletion of chromosome 7p11.23 
and is also detectable by FISH [8]. The cardio-vascular 
defects in this syndrome were found to be due to loss of 
elastin, and mutations in elastin were identified in indivi-
duals with isolated supravalvar aortic stenosis [9, 10]. 
Although FISH is a powerful technique, it can only be 
utilized when there is a clinical suspicion that the constel-
lation of symptoms is caused by a specific microdeletion, 
allowing one to target this area of interest. As such, FISH 
cannot be applied genome-wide to find novel chromosomal 
abnormalities.  
SINGLE GENE MUTATIONS 
Single Gene Defects Associated with Syndromes 
  With advances in genetic technology and the completion 
of the Human Genome Project, single gene defects leading to 
syndromes associated with congenital heart disease have 
been elucidated and they are summarized in Table 2. Some 
of the earliest work was the discovery that mutation of 
Fibrillin 1 (FBN1) was the cause of Marfan syndrome, 
which is characterized by progressive aortic root dilation 
with a predisposition to dissection, lens dislocation, and 
skeletal anomalies [11]. The genetic etiology was discovered 
using traditional positional cloning approaches and required 
the identification of a large kindred with multiple affected 
members along with a unique phenotype. Since then the 
genetic basis of numerous syndromes have been identified 
and each is characterized by a unique constellation of birth 
defects. Holt-Oram syndrome, characterized by atrial and 
ventricular septal defects, progressive atrioventricular 
conduction system disease, and radial limb and thumb 
anomalies, is associated with mutations in the transcription 
factor, TBX5 [12]. Alagille syndrome, caused by mutations 
in JAG1, a gene encoding a ligand in the Notch signaling 
pathway, is characterized by intrahepatic bile duct paucity 
and cardiovascular malformations, including peripheral 
pulmonic stenosis, pulmonary valve stenosis, and tetralogy 
of Fallot [13, 14]. Consistent with this, mutations in a 
NOTCH receptor, NOTCH2, have also been identified in 
subjects with Alagille syndrome [15]. The phenotype of 
Noonan syndrome consists of cardiac defects, typically 
pulmonary valve stenosis and hypertrophic cardiomyopathy, 
Table 1.  Common Syndromes Resulting from Anueploidy and Microdeletions 
Syndrome  Cardiac Anomalies  % with CHD  Other Clinical Features 
Trisomy 13  ASD, VSD, PDA, HLHS  80%  Microcephaly, holoprosencephaly, scalp defects, severe mental retardation, 
polydactyly, cleft lip or palate, genitourinary abnormalities, omphalocele, 
microphthalmia 
Trisomy 18  ASD, VSD, PDA, TOF, DORV, 
CoA, BAV 
90-100%  Polyhydramnios, rocker-bottom feet, hypertonia, biliary atresia, severe 
mental retardation, diaphragmatic hernia, omphalocele 
Trisomy 21 (Down 
syndrome) 
ASD, VSD, AVSD, TOF  40-50%  Hypotonia, developmental delay, palmar crease, epicanthal folds 
Monosomy X (Turner 
Syndrome) 
CoA, BAV, AS, HLHS  25-35%  Short stature, shield chest with widely spaced nipples, webbed neck, 
lymphedema, primary amenorrhea 
47, XXY (Klinefelter 
Syndrome) 
PDA, ASD, mitral valve prolapse  50%  Tall stature, hypoplastic testes, delayed puberty, variable developmental 
delay 
22q11.2 deletion  
(DiGeorge Syndrome) 
IAA Type B, aortic arch anomalies, 
truncus arteriosus, TOF 
75%  Thymic and parathyroid hypoplasia, immunodeficiency, low-set ears, 
hypocalcemia, speech and learning disorders, renal anomalies 
7q11.23 deletion 
(Williams-Beuren 
Syndrome) 
Supravalvar AS, PPS  50-85%  Infantile hypercalcemia, elfin facies, social personality, developmental 
delay, joint contractures, hearing loss 
ASD, atrial septal defect; VSD, ventricular septal defect; PDA, patent ductus arteriosus; HLHS, hypoplastic left heart syndrome; TOF, tetralogy of Fallot; DORV, double outlet right 
ventricle; CoA, coarctation of aorta; BAV, bicuspid aortic valve; AVSD, atrioventricular septal defect; IAA, interrupted aortic arch; AS, aortic stenosis; PPS, peripheral pulmonic 
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as well as cognitive disability, characteristic facies, and 
bleeding disorders. Initially, mutations in PTPN11, a gene 
involved in Ras signaling, were identified to be the cause of 
50% of cases [16]. Subsequent studies have found that muta-
tions of other genes involved in the Ras signaling pathway 
including RAF1, SOS1, and KRAS were also associated 
with a similar spectrum of disease [17-20]. In addition, 
LEOPARD and Costello syndromes, which exhibit a similar 
phenotype as Noonan syndrome, are the result of mutations 
in Ras signaling pathway members [21-24]. Another syn-
drome characterized by dysmorphic facies and digit 
anomalies along with congenital heart disease (specifically 
patent ductus arteriosus) was found to be caused by mutation 
in the transcription factor, TFAP2 using traditional approa-
ches after the identification of large kindreds [25]. Lastly, 
heterotaxy syndrome, which is randomization of cardiac, 
pulmonary and gastrointestinal situs, is frequently associated 
with congenital heart disease, specifically atrioventricular 
septal defects, and transposed great arteries. A subset of 
these cases have been identified to be caused by mutations in 
ZIC3, CFC1, ACVR2B, and LEFTYA, genes that regulate 
left-right asymmetry in the developing embryo [26]. 
Single Gene Defects Associated with Non-syndromic 
Cardiac Malformations 
  More recently, single gene defects associated with isola-
ted or non-syndromic congenital heart disease have been 
discovered (Table 3). Kindred studies revealed that muta-
tions in NKX2.5 lead to isolated atrial septal defects with 
atrioventricular conduction delay [27]. Mutations in GATA4, 
a zinc finger transcription factor known to interact with   
 
Table  3.  Non-Syndromic CHD Resulting from Single Gene 
Defects 
Cardiac Anomalies  Gene 
ASD, atrioventricular conduction delay, TOF, 
tricuspid valve abnormalities 
NKX2.5 
ASD, VSD  GATA4 
ASD, hypertrophic cardiomyopathy  MYH6 
Cardiac septation defects associated with PHTN  BMPR2 
Endocardial cushion defects  CRELD1, ALK2 
BAV, early valve calcification  NOTCH1 
d-TGA PROSIT-240 
ASD, atrial septal defect; TOF, tetralogy of Fallot; VSD, ventricular septal defect; 
TGA, transposition of the great arteries; BAV, bicuspid aortic valve; PHTN, 
pulmonary hypertension 
 
NKX2.5, have been linked to isolated atrial septal defects 
without conduction system abnormalities. Interestingly, a 
mutation in Gata4 specifically disrupted an interaction with 
TBX5 suggesting that mutations in any of these interacting 
transcription factors can lead to CHD [28]. Myosin heavy 
chain 6 (MYH6) mutations have been identified as another 
cause of atrial septal defects [29]. MYH6  is known to be 
activated by TBX5 and GATA4, suggesting that mutations 
in the common downstream targets of these genes may be a 
cause of cardiac septation defects. Several genes have been 
implicated in the genetic etiology of atrioventricular septa-
tion defects including CRELD1, ALK2, and BMPR2 [30-
Table 2.  Common Syndromes Associated with CHD Resulting from Single Gene Defects 
Syndrome  Cardiac Anomalies  Other Clinical Features  Causative Gene(s) 
Noonan Syndrome  PS with dysplastic pulmonary 
valve, AVSD, HCM, CoA 
Short stature, webbed neck, shield chest, developmental delay, 
cryptorchidism, abnormal facies 
PTPN11, KRAS, RAF1, 
SOS1 
Costello Syndrome  PS, HCM, cardiac conduction 
abnormalities 
Short stature, developmental delay, coarse facies, nasolabial 
papillomata, increased risk of solid organ carcinoma 
HRAS 
LEOPARD 
Syndrome 
PS and cardiac conduction 
abnormalities 
Lentigines, hypertelorism, abnormal genitalia, growth retardation, 
sensorineural deafness 
PTPN11, RAF1 
Alagille Syndrome  PS, TOF, ASD, peripheral 
pulmonary stenosis 
Bile duct paucity, cholestasis, typical facies, butterfly vertebrae, 
ocular anomalies, growth delay, hearing loss, horseshoe kidney 
JAG1, NOTCH2 
Marfan Syndrome  Aortic root dilatation and 
dissection, mitral valve prolapse 
Tall stature, arachnodactyly, pectus abnormality, scoliosis, ectopia 
lentis, spontaneous pneumothorax, striae, dural ectasia 
FBLN, TGFBR1, TGFBR2 
Holt-Oram Syndrome  ASD, VSD, AVSD, progressive 
AV conduction system disease 
Preaxial radial ray malformations (thumb abnormalities, radial 
dysplasia) 
TBX5 
Heterotaxy Syndrome  DILV, DORV, d-TGA, AVSD  intestinal malrotation  ZIC3, CFC1 
Char Syndrome  PDA  Dysmorphic facies and digit anomalies  TFAP2b 
CHARGE Syndrome  ASD, VSD, valve defects  Coloboma, choanal atresia, developmental delay, genital and/or 
urinary anomalies 
CHD7, SEMA3E 
PS, pulmonic valve stenosis; AVSD, atrioventricular septal defect; HCM, hypertrophic cardiomyopathy; CoA, coarctation of aorta; TOF, tetralogy of Fallot; ASD, atrial septal 
defect; VSD, ventricular septal defect; AV, atrioventricular; DILV, double inlet left ventricle; DORV, double outlet right ventricle; TGA, transposition of the great arteries; PDA, 
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32]. Additionally, mutations in NOTCH1 have been identi-
fied as a cause of aortic valve malformations, including 
bicuspid aortic valve and early aortic valve calcification, via 
genome-wide linkage analysis of an affected family. Interes-
tingly, family members with trileaflet aortic valves and 
NOTCH1 mutations also developed early valve calcification, 
indicating that NOTCH1 also plays a role in valvular 
calcification [33]. The identification of more severe cyanotic 
forms of non-syndromic CHD has been limited. The gene 
PROSIT240 was found to be disrupted by a balanced 
translocation in a patient with d-transposition of the great 
vessels and mental retardation, and subsequently additional 
patients with isolated d-TGA were found to have mutations 
in this gene [34]. These new developments demonstrate that 
single-gene defects can lead to isolated congenital heart 
disease, and reveal more about molecular pathways impor-
tant in cardiac morphogenesis. 
COPY NUMBER VARIATIONS IN CONGENITAL 
HEART DISEASE 
  Despite these advances and discoveries, the vast majority 
of individuals with CHD do not have single gene defects. 
With the sequencing of the human genome, new information 
about genetic diversity has been revealed. One type of 
genetic variation, the copy number variation (CNV), consists 
of intermediate-size duplications and deletions that lead to 
changes in gene dosage and affect about 12% of the human 
genome [35]. CNV are considered polymorphisms when 
present in >1% of the population, and are more likely to be 
disease-associated when occurring in <1% of individuals. 
Comparative genomic hybridization (CGH), a DNA micro-
array-based methodology can detect these submicroscopic 
CNV genome-wide.  
Copy Number Variation in Human Disease 
  The presence of CNV encompassing a variety of diffe-
rent genomic regions has been shown to be strongly asso-
ciated with diseases such as autism, schizophrenia, and deve-
lopmental delay, along with being identified in individuals 
with multiple anomalies. Sebat and colleagues performed 
whole genome array CGH on subjects with autism spectrum 
disorders and their unaffected siblings and found that de 
novo but individually rare CNVs were significantly 
associated with autism [36]. More recently, a microdeletion 
or reciprocal microduplication of chromosome 16p11.2 was 
identified by array CGH in a large population of families to 
be significantly associated with autism in 1% of cases [37]. 
Similar results have been obtained using array CGH in 
individuals with schizophrenia where rare microdeletions 
and microduplications are present significantly more often in 
individuals with schizophrenia than in related controls. 
These CNV predominantly modified genes involved in 
neurodevelopment, suggesting that they are contributing to 
the development of schizophrenia [38, 39]. Array CGH has 
also been used to study idiopathic mental retardation, as well 
as mental retardation associated with dysmorphism. Multiple 
studies have detected abnormal chromosomal copy number 
associated with these clinical phenotypes, ranging from 4% 
to 17% of those studied [40, 41]. Across a wide spectrum of 
diseases, array CGH has developed into a useful tool to 
detect submicroscopic chromosomal anomalies that lead to 
disease or increase disease susceptibility.  
Copy Number Variation in Congenital Heart Disease 
  Unique copy number variations are associated with 
congenital cardiac malformations. Initial studies have identi-
fied CNVs in children with CHD along with multiple other 
congenital anomalies. CHARGE syndrome, a constellation 
of anomalies including coloboma of the eye, heart defects 
including conotruncal and aortic arch malformations, choa-
nal atresia, growth retardation, and ear abnormalities, was 
recently found to be due to a microdeletion on chromosome 
8p21 [42]. Whole-genome array was initially used to screen 
the entire genome of individuals with CHARGE syndrome 
and detected a 2.3 Mb microdeletion on chromosome 8p21 
in one individual. Subsequent sequencing of the critical 
region revealed heterozygous mutations in CHD7, a gene 
which encodes for a chromodomain helicase DNA-binding 
protein that is expressed during embryogenesis, in 10 
subjects, suggesting that CHD7 haploinsufficiency leads to 
CHARGE syndrome [42]. Subsequent studies, identified 
pathogenic mutations in CHD7 in over 50% of a population 
of 110 individuals with CHARGE syndrome (Table 2) [43]. 
Array CGH helped to identify the gene responsible for the 
majority of cases of this syndrome, demonstrating the impor-
tance of this methodology in gene discovery, especially 
when studying rare diseases. 
  Using array CGH, Thienpont and colleagues studied 
sixty patients with CHD and other birth anomalies and 
normal chromosomes by standard cytogenetics and detected 
rare CNV in 30%. While some of these CNV were in regions 
known to contain genes critical for cardiac development such 
as  NKX2.5 and NOTCH1, the majority occurred where no 
known cardiac genes were located [44]. Causation was sup-
ported when CNV contained genes important in cardiac 
development or when they arose de novo, and this analysis 
suggested that 17% of the patient population harbored 
causative CNV. The remaining 13% of CNVs were inherited 
from unaffected parents, so causation could not be estab-
lished. This study demonstrated that CNV are associated 
with CHD that occurs in association with other anomalies or 
developmental delay. 
  In another study, high-resolution whole-genome array 
CGH was performed to detect rare CNV in 40 individuals 
with CHD and normal karyotypes. Twenty had CHD and 
other anomalies or developmental delay, while the others 
had isolated CHD. Large causative CNV were identified in 
five individuals (25%), all with CHD and neurological 
abnormalities or developmental delay. The risk of having 
disease-causing CNV increased to 45% in those with neuro-
logical abnormalities or developmental delay. These results 
demonstrate that large and likely causative CNV exist in 
individuals with CHD especially when developmental delay 
or neurological anomalies are also present [45]. These recent 
studies demonstrate that using whole-genome array CGH to 
detect disease-associated CNV in individuals with CHD and 
neurologic anomalies can be useful if conventional genetic 
evaluation including karyotype is normal. 
  Copy number variations have also been identified in 
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studied 105 individuals with various types of isolated CHD 
and no other anomalies or evidence of developmental delay 
to whole genome array CGH and detected 18 rare CNV. The 
majority were duplications, in contrast to those found in 
syndromic CHD, which are predominantly deletions. 
Additionally, 44% were familial, also occurring in parents 
with no evidence of CHD, perhaps indicating that these CNV 
increase susceptibility to CHD but require other modifying 
factors to manifest the phenotype [46]. This demonstrates 
that rare CNV may be an important genetic contributor to 
isolated CHD, but in light of the significant cost for array 
CGH and inconclusive results to provide accurate genetic 
counseling, it is not yet clinically indicated in cases of isola-
ted CHD. 
SINGLE NUCLEOTIDE POLYMORPHISMS IN 
CONGENITAL HEART DISEASE 
  While copy number variations represent one type of 
genetic diversity, single nucleotide polymorphisms (SNPs) 
represent another. SNPs are changes in single nucleotides 
found throughout the genome; data from the Human Genome 
Project estimates that 90% of human genetic variation results 
from SNPs [47]. These may occur in coding or non-coding 
regions of the genome, and each SNP does not necessarily 
affect gene function. A collection of SNPs in a particular 
genomic region each of which is highly non-randomly 
associated with the others is referred to as a haplotype. Some 
SNPs have been shown to modify response to pharma-
ceutical agents, while others have been implicated in suscep-
tibility to disease. Whole genome association studies have 
detected SNPs that increase susceptibility to common 
diseases such as cancer, diabetes, and coronary artery 
disease, and replication studies have confirmed these asso-
ciations in multiple cohorts. SNPs that influence the 
development of CHD have also been identified, though the 
field is still in the early stages of development. The number 
of subjects with CHD that can be studied is relatively small 
due to its relative infrequency, significant phenotypic 
variability, and the early lethality that existed only until the 
last couple of decades, as such the statistical power that can 
be generated from whole genome studies is low. As such 
until now, SNP association studies in CHD have focused on 
detecting polymorphisms in candidate genes thought to be 
involved in the development of CHD. 
  The role of folate metabolism in the development of 
CHD is one area where initial association studies focused. 
Maternal folate supplementation is known to reduce the 
incidence of neural tube defects in offspring, and by a 
similar mechanism, appears to decrease the incidence of 
CHD [48]. A common polymorphism in the methylenete-
trahydrofolate reductase (MTHFR) gene at position 677 
changes a cytosine to a thymine (C677T) and leads to 
decreased activity of the enzyme. This SNP, found in about 
10% of individuals of Northern European origin, has been 
investigated in multiple studies to determine if it confers an 
increased risk for CHD. A recent meta-analysis examining 
all studies of this MTHFR polymorphism failed to find an 
association between the presence of the homozygous C677T 
allele in either mothers or offspring and increased risk for 
CHD [49]. Due to the small sample sizes in the individual  
 
studies, heterogeneity in types of CHD, and unknown pre-
sence of maternal folic acid supplementation, these results 
remain inconclusive, and further study is required.  
  In numerous mouse models, vascular endothelial growth 
factor (VEGF) has been shown to be critical for normal heart 
development. Three SNPs in the promoter of VEGF 
(C2578A, G1154A, and C634G) had previously been shown 
to be a modifier of 22q11 deletion syndrome in a candidate-
gene based study and this haplotype is associated with lower 
VEGF levels in vivo [50, 51]. Following this, family based 
studies using 148 trios found that the low expression VEGF 
haplotype was transmitted more often than expected to 
affected children suggesting that it may play a role in the 
development of isolated TOF [52]. This has been followed 
by the examination of VEGF SNPs with other types of CHD. 
The polymorphism at position -634 was found to be asso-
ciated with ventricular septal defects in a Chinese population 
[53] and two other VEGF SNPs (-460T/C and +405G/C) 
also associated with decreased VEGF expression have been 
reported to be associated with valvuloseptal defects in a 
small case-control study [54]. Similar to as was seen with 
polymorphisms in MTHFR, a recent meta-analysis failed to 
demonstrate an association with VEGF genetic variations 
and CHD [55].  
FUTURE DIRECTIONS 
  From congenital heart defects due to chromosomal 
aneuploidy to single gene defects causing isolated CHD, 
genetics has a much greater influence on the development of 
various types of CHD than previously appreciated. We are 
just beginning to understand the significance of copy number 
variations in CHD, and this field will likely serve as an 
important mechanism for gene discovery as the resolution of 
array CGH improves. Although whole-genome association 
studies using SNPs have been useful in studies of coronary 
artery disease, the relatively uncommon incidence of CHD 
and its phenotypic heterogeneity may limit their usefulness 
in single institution studies due to lack of power. Candidate 
gene association studies for etiologic and susceptibility 
genes in CHD will continue to reveal new genetic variations 
that may modify risk, but these studies will require 
replication in ethnically diverse populations to be validated. 
As the cost of DNA sequencing decreases, we will ultimately 
be able to sequence the entire genome, which may lead to an 
increase rate of gene discovery in CHD. As new genetic 
abnormalities associated with CHD are identified, develop-
ment of international collaborative databases with pheno-
typic information will allow for the study of clinical 
outcomes and prognosis based on genetic backgrounds. As 
more knowledge is gained about the influence of genetics on 
CHD, strategies for the prevention of CHD or prediction of 
outcome will develop that will prove beneficial for future 
generations of children affected by CHD. 
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